Sanofi pays $260Mn to terminate its partnership with Lexicon
Category: #healthcare  By Mateen Dalal  Date: 2019-09-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi pays $260Mn to terminate its partnership with Lexicon

The announcement resulted in a sudden surge of Lexicon’s shares, which went up by 37.8% to $2.37 in after-hours trading.

France-based multinational pharma conglomerate Sanofi SA, is reportedly liable to pay a sum of $260 million to Lexicon Pharmaceuticals Inc., an American biopharmaceutical firm that develops novel treatments. It has been speculated that the payment has been made on the grounds of the terminated partnership between both the companies. Incidentally, their joint venture focused on the creation of Zynquista, an oral dual inhibitor of two proteins responsible for the treatment of diabetes.

According to reports, the French company will pay $208 million upfront and the remaining within a year to Lexicon. Reportedly, Lexicon was likely to get up to $1.4 billion in milestone payments under this venture.

Speaking on the announcement, Lonnel Coats, President and Chief Executive Officer, Lexicon, said that the company’s four-year alliance with Sanofi was very beneficial and has helped them achieve many positive milestones, such as Zynquista gaining marketing approval for type 1 diabetes and furthering into the advanced stage studies in type 2 diabetes in Europe.

He added that regaining global rights enabled it to improve its efforts to accomplish the complete value of the Zynquista program as it geared up for regulatory filings in Europe and the U.S. in type 2 diabetes, with new data approaching from the ongoing core Phase 3 studies and from two long-term outcomes studies with potential for showing renal and cardiovascular benefits.

Reportedly, the drug received approval from the European Union for using the drug to treat type 1 diabetic patients but was unsuccessful in gaining the U.S. approval due to some concerns raised by the experts on the risk of diabetic ketoacidosis (DKA).

For the record, DKA is a serious disease in which acids known as ketones are developed when the body starts to neglect glucose and consumes fat in order to produce energy.

As per reliable reports, Lexicon, following this move, will redeem its worldwide rights for the commercialization and advancement of Zynquista in both type 2 and type 1 diabetes.

Source Credit: https://www.nasdaq.com/article/sanofi-to-pay-lexicon-260-mln-for-terminated-partnership-20190910-01024

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

FDA approves three drugs for counter use through Rx-to-OTC process
FDA approves three drugs for counter use through Rx-to-OTC process
By Mateen Dalal

The U.S. FDA (Food and Drug Administration) has reportedly approved three drugs as an over-the-count...

CheckMate-025 study reveals positive results of Opdivo treatment trial
CheckMate-025 study reveals positive results of Opdivo treatment trial
By Mateen Dalal

Bristol-Myers demonstrates five year follow up results from CheckMate-25 Phase 3 study for Opdivo ...

Abeona presents positive interim data from ongoing MPS III trials
Abeona presents positive interim data from ongoing MPS III trials
By Mateen Dalal

Abeona Therapeutics Inc., a leading biopharmaceutical firm focusing on cell and gene therapy, has re...